# US 2025/0082749 A1 · Vaccine Adjuvant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082749 A1
- Document ID: US20250082749A1
- Status: Published application
- Kind: A1
- Application number: 18/808,565
- Filed: 2024-08-19
- Published: 2025-03-13
- Earliest claimed: 2016-10-21
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Bruce Steven Klein; Huafeng Wang; Marcel Wuethrich; Tristan Theodore Brandhorst
- Web page: https://patentgrep.com/patent/US20250082749A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/0002: {Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A Dectin-2 ligand vaccine adjuvant and a method of making and using the Dectin-2 ligand vaccine adjuvant in a vaccine to immunize a patient are disclosed. Also discloses is a vaccine composition comprising a Bl-Eng2 antigen and methods of using the vaccine composition to immunize a subject against a fungal infection.

## Claims

### Claim 1

A vaccine suitable to immunize a patient comprising an adjuvant, wherein the adjuvant is a Dectin-2 ligand.

### Claim 2 (depends on 1)

The vaccine of claim 1, wherein the Dectin-2 ligand is a glycoprotein.

### Claim 3 (depends on 1)

The vaccine of claim 1, wherein the Dectin-2 ligand is Bl-Eng2.

### Claim 4 (depends on 3)

The vaccine of claim 3, wherein Bl-Eng2 comprises SEQ ID NO:1.

### Claim 5 (depends on 3)

The vaccine of claim 3, wherein Bl-Eng2 comprises O-linked glycosylations.

### Claim 6 (depends on 1)

The vaccine of claim 1, wherein the vaccine immunizes a patient against a fungal infection.

### Claim 7 (depends on 1)

The vaccine of claim 1, wherein the vaccine comprises glucan particles.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

A method of preparing a vaccine comprising the steps of,
(a) preparing a pharmaceutically acceptable vaccine stabilizer; and
(b) introducing to the vaccine stabilizer a suitable antigen and an adjuvant, wherein the adjuvant is a Dectin-2 ligand.

### Claim 11 (depends on 1)

A method of protecting a patient from an infection comprising the steps of:
(a) obtaining the vaccine of claim 1, wherein the vaccine comprises an adjuvant and a suitable antigen, wherein the adjuvant is a Dectin-2 ligand; and
(b) providing a therapeutically effective amount of the vaccine to a subject, wherein the subject is protected from the infection.

### Claim 12

(canceled)

### Claim 13 (depends on 12)

The method of claim 12, wherein the antigen is a fragment of calnexin and the fungi is selected form the group consisting of Histoplasma, Coccidiodes, Paracoccidiodes, Penicillium, Blastomyces, Sporothrix, Aspergillus, Pneumocystis, Magnaportha, Exophiala, Neuroaspora, Cryptococcus, Schizophyllum, and Candida.

### Claim 14

A vaccine composition comprising B1-Eng2 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 14)

The vaccine of claim 14, wherein Bl-Eng2 comprises SEQ ID NO:1.

### Claim 16 (depends on 14)

The vaccine of claim 14, wherein Bl-Eng2 comprises O-linked glycosylations.

### Claim 17

(canceled)

### Claim 18 (depends on 14)

The vaccine of claim 14, wherein the vaccine additionally comprises an adjuvant.

### Claim 19 (depends on 18)

The vaccine of claim 18, wherein the vaccine comprises incomplete Freunds adjuvant.

### Claim 20 (depends on 14)

The vaccine of claim 14, wherein the vaccine comprises a fragment of Bl-Eng2.

### Claim 21 (depends on 14)

A method of protecting a patient from an infection comprising the steps of:
(a) obtaining the vaccine of claim 14, wherein the vaccine comprises Bl-Eng2; and
(b) providing a therapeutically effective amount of the vaccine to a subject, wherein the subject is protected from the infection.

### Claim 22 (depends on 21)

The method of claim 21, wherein the infection is a fungal infection.

### Claim 23 (depends on 21)

The method of claim 21, wherein Bl-Eng2 comprises SEQ ID NO:1.

### Claim 24 (depends on 21)

The vaccine of claim 21, wherein Bl-Eng2 comprises O-linked glycosylations.
